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Acute coronary artery dissection causes unpredictable 
abrupt vessel closure and ischemia during ~e~c~ta~eoMs 
transluminal coronary angioplasty. De continued im- 
provements in equipment and the tech aspects of the 
procedure, abrupt vessel closure still occurs in approxi- 
mately 2% to 10% of all patients und 
plasty (1). Hn the 198~1986 Nasional 
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I. 
tied kmtaneous Translutinal Coronary A~~~~~~ty 
strq , its im:dence was 6.8%; in these patients, 32% re- 
quired emeyency coronary artery ypass urgery, 42% 
in-hospital rs:focardial nfarction and 5% died before hospitaal 
discharge. i-::: 5 months, 45.9% of these patients had bypass 
surgery, 41% :lad mysc 
rates of adverse events have been r
~~vest~~ato~s (2-4) fohsi 
rnnary stenls with a variety of 
reat dissections oracute clos 
y ~rovidi~g a prostbe~ic 
can correct he geometric Pimitati 
not uncommon!y seen after angi 
coronary artery dissection. The Gianturco 
coronary stent (Gianturco- ubin Flex-Stent, Cook Enc.) 
0735iOYi/93/.%.0 
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has been under laboratory and clinical investigation since 
1985 (8-15). In May 1992, the Circulatory System Devices 
Advisory Panel of the Food and Drug Administration rec- 
ommended commercial approval ofthis device to treat acute 
or threatened vessel closure. The purpose of this study is to 
report the early multicenter experience with this tent. The 
immediate and dmonth efficacy of the device and the 
incidence of the complications of death, myocardial infarc- 
tion, emergency coronary artery bypass surgery and recur- 
rent ischemic events are presented. 
r 1988 through June 1991, 
d in a mlnlticenter clinical trial of the 
&mm long balloon-expandable flexible Gianturco-Roubin 
coronary stent at 19 investigative c nters Lroughout he 
United States (see Appendix). The indication for stenting 
was acute or threatened vessel closure compltcating a con- 
ventional coronary ngioplasty procedure. Four hundred 
ninety-four of these patients had one or more coronary 
stents implanted. All patients gave written Informed consent 
for implantation f the investigational device. The study 
protocol was approved by the Institutional Review Board of 
each investigative c nter. 
Definitions. Acute vessel closure, defined as occlusion of 
a vessel with Thr,lmbolysis in Myocardial Infarction trial 
(TIMI) grade 1 or 0 flow, was based on the angiographic 
appearance of the vessel immediately b&I-e stent insertion. 
Threatened vessel closure was tiefined as deterioration in 
arteriographic, electrocardiographic (ECG), hemodynamic 
or clinical indicators after coronah y angioplasty and required 
at least wo of the following criteria: I) postangioplasty 
residual steno& rSO%, 2) TlM: grade 2 flow, 3) significant 
dissection, or4) clinical evidence ofischemia (that is, typical 
angina or ECG changes). 
Zmmedinre s ngiograplrk success of the angioplastylstent 
nMlre&.z6 ..,no A&LNI ..- ..-.I..-*: - Y.vrruurr -V-U U*IIII~U QJ ~r;uucr~uii i# Chii&x stenosis by 
220% and a residual diameter stenosis ~~50% after the 
procedure. Ang.iographic yestenosis was defined as >50% 
diameter narrowing at the stent site at any angiographic 
follow-up study. Stenosis d ameter was measured with elec- 
tronic digital czlipers. Measurements were taken from the 
angiographic v ew that showed the lesion most clearly and 
with the most severe narrowing, 
In-hospitaal clinical success was defined as immediate 
angiographic success with no major ischemic complication 
(myocnrdial nfarction, bypass urgery or death). 
MYL cavdial hfarcrion was defined as the development of 
new pathologic Q waves (240 ms) or elevation of creative 
kinase to more than twice the normal upper limit with an 
elevated creatine kinase-MB fraction after stent placement, 
or both. 
ercutaneGus translum coronary angioplas~y proce- 
dum Coronary angioplasty was performed using conven- 
tional techniques. The preangioplasty medical regimen 
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evolved uring the course of the trial 
either dihiazem or nifedipine the 
and soluble aspirin and d~~y~~ 
procedure. On the basis of the 
trials, stent thrombosis was observe 
the use of soluble aspirin, rather than e~te~c~eo~t~ 
plus d~py~damo~e (75 mg orally, three times daily) 
two 325-mg doses of scluble aspirin were regularly given 
(one dose on the morning of t 
lesions determined to be at hig 
often pretreated with dextran 
target activated clotting 
The coronary angiopl 
standard techniques ate 
the artery or an unstable angiograp~~c appearance d velop 
during the course of the procedure, patients were genera 
further treated with prolonged inflations with either the same 
balloon or with a balloon OS rger. 
the operator, a perfusion b syst 
When appropriate, the patient proceed 
implantation. 
intravenously and the infusion co&inued at 
therapeutic infusion of heparin was reestablished. 
Stenting we. Gianturco-Ro~bi~ flexible coro- 
nary stent een ribed in detail ~rev~o~s~y (8). 
Briefly, this stent is co ed of a continuous single strand 
of ON&in. (0.15 cm) diameter surgical grade stainless steel 
wire. The wire is formed into a cylinder of i~terdig~tati~g 
loops (Fig. I). This design provides high hoop strength and 
ensures that stents will not shorten with radial expansion. 
The stents used in this study have an effective length of 
18 mm. Stems are suppiied in nominai expanded diameters 
of 2, 2.5, 3, 3.5 and 4 mm. Each stent is supplied tightly 
prewrapped around apolyethylene compliant balloon cath- 
eter. The balloons are 30 mm long and have nominal inflated 
diameters 0.5 mm larger than the nominal expanded diame- 
ter of the stent. 
The deflated balloon/stent catheter is relatively flexible 
and can be positioned atthe target si e by a slightly modified 
over the wire technique. The profile of the stentlballoon 
catheter requires large lumen 8F guiding catheters for the 2-, 
2.5- and 3-mm stents and 1 umen 9F guiding catheters 
for the 3.5-and 4-mm stents. reover, the selected guiding 
catheter must provide optimal backup support. Trackabiiity 
of the device is enhanced by using 0.018-in. (0.045 cm) 
coronary guide wires. The stent./balloon catheter was care- 
fully advanced tothe lesion and the balloon was inflated to 
5 to 8 atm depending on the stent ~iamet~~. 
balloon deflation was ensured, the balloon catheter was 
gently advanced approximately 1 mm to divengage the stent, 
s showing the stent before and after 
is co~~~se~ of a single strand of surgic 
around the delivery ball 
place. Redrawn, with 
drawn leaving the expa 
rapby was repeated and f?lrther i 
inside the stent if necessary to p 
result. Hf the balloon could not 
position, the stent was re~~oved by wit~~rawi~g t to the tip 
of the guiding catheter and remov~~g theste~t/~a~loon cath- 
eter and the guiding catheter as a unit t 
sheath. At the end of the proced 
moved, sheaths were left in place a 
to the coronary care or angioplasty nursing unit. An ECG 
was recorded immediately after a~gio~iasty and daily for 2 
days. Creatine kinase and isoenz:me estimations were per- 
formed immediately and every 8 II for 24 b. 
In patients with angiographic evidence of intracoronary 
thrombus, an intracoronary ~rQ~~~ase infusion was admin- 
istered. After the procedure, administration f heparin was 
discontinued or decreased until the activated clotting time 
was ‘150 s and the sheaths removed. Early in the study, the 
sheaths were left in an the heparin infusion was continued 
until the next day. Later in the study, sheaths were removed 
at 4 to 4 h after the procedure when the activated clotting 
time had decreased to~:I50 s. Pressure was maistained on 
the groin for 1. h, at which time the heparin infusion was 
restarted. Titration with Coumadi~ (warfarin) was initiated. 
Heparin administration was continued until the prothrombin 
time was >I7 s on two blood samples taken 12 h apart. 
was made before a
ments were taken m the c~~~ea~glogram most closely 
precedi~~ stent place , A cinea~g~ogram oft 
occlusion event was always available. Th 
stenosis reported for the acute closure 
eiving stents were requested toreturn for 
angiographic follow-up examination at 4 months. So 
underwent a~giogra~hy earlier for 
ecause of the recL 
up, c~~eangi~grams were ta 
bie during 
By&. C 
the z test (at (Y = 0.05 
evaluatc the digerence in the incidence of 
betweerl ,he group of patients who i.mder% 
acute closure and the group treat.ed for threatened closure. 
Chi-square analysis was employed to evaluate he in 
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ECG C AngInaa Pentorbs 
(n=i72) (n=2W) 
Figure 2. Schematic representation of the patients who underwent 
stenting for threatened vessel closure stratified according to the 
presence of dissection, angina pectoris or electrocardiographic 
(ECG) changes before stent placement. 
of stem diameter and the implantation f multiple stents on 
the incidence of thrombosis and restenosis of the stented 
artery. 
Study patients. Stent placement was attempted in 518 
patients. One or more stents were implanted in a single 
procedure in494 patients (95.4%). Twelve of these patients 
received stents during each of two separate procedures. 
There were 349 men and 145 women. The mean age was 59 k 
II years (range 27 to 85) with I71 (34.6%) aged 265 years. 
Multivessel disease was reported in 275 patients (55.7%). 
The initial coronary angioplasty procedure was performed as
an elective procedure in 273 patients (55.2%) and under 
conditions of unstable angina i  I57 (31.8%). Thirty-seven 
patients (7.5%) were reported with evolving myocardial 
infarction before angioplasty. Data on left ventricular ejec- 
tion fraction (mean value 53 f 11%) were available for 372 
patients (75.3%). 
The indication for stent implantation was acute vessel 
closure in 156 patients (3 1.6%) and threatened closure in 337 
patients (68.2%). Of those patients receiving a stem for 
threatened closure, dissection was reported in 277 (82.2%) 
before stent implantation a d either dissection, augina or 
ECG changes were present i  323 (95.8%) (Fig. 2). 
Lesion and steat characteristics. The majority of stems 
(92.8%) were implanted in native vessels (Table I). A broad 
representation f left anterior descending (36.3%), ri;;ht 
coronary (36.3%) and left circumflex (19%) arteries a:re 
stented. Similarly, the series includes a cross sect.ion of 
anatomic and morphologic characteristics, ncluding chronic 
occlusions (12.8%), long stenoses >15 mm (17.9%) severe& 
tortuous lesions (8. is), branch point stenoses (22.9%) anti 
lesions with visible thrombus before stenting :28.1%). Nom- 
inal normal vessel diameter was <3 mm for 38.4% of the 
Tnbfe 1. Distribution of the Diameters of %:nts Used ad the 
Vessels in Which They Were Implanted -- 
Stem Diameter (mm) 
Vessel 2 2.5 3 3.5 4 Total 
LAD i7 79 83 21 I 201 
RCA 2 49 IQ2 36 12 201 
LCX 1 51 46 6 1 105 
LMCA 0 3 3 1 0 1 
Graft o RCA 0 4 3 3 6 16 
Graft o LCx 0 2 3 6 3 14 
Graft o LAD 0 I 1 4 4 10 
Total 20 189 241 71 27 554 
LAD = left anterior desceuding coronary artery; LCx = left circumflex 
coronary artery: LMCA = left main coronary artery; RCA = right coronary 
artery. 
vessels tented. Of the stems placed, 37.1% were 2 or 
2.5 mm in diameter, 43.5% were 3 mm in di 
were 3.5 or 4 mm in diameter. Thirty-six 
stems placed in grafts. Four of these 3 
stents placed in the same graft. Fifty-two 
two stents during either a single procedure or duri 
different procedures and five patients re 
Table 2 summarizes data from the patients receiving 
eighty-one (97.3%) ofthe 494 patients with a stem met the 
definition for immed angiographic success of the angio- 
p~astyiste~ti~g proce . §t~~t~~~ resulted in an i ediate 
angiographic improvement in the diameter stenosis from 
Table 2. Summary of Patients Receiving Multiple Stents and the 
Vessels Stented 
Vesseis Stemed 
No. of Patients Receiving Two Stents 
-_ 
.- 







Graft, RCA/graft. RCA 
Graft, LCxlgraft. LCx 



























*I)ne patient received two stents in his first procedure and a third stent in 
a second procedure. Abbreviations as in Table I. 
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___- 
Death 4 2.6 7 2.1 11 2.2 0.983 
Bypass surgery 
Emergency 12 7.7 9 2.7 21 4.3 
Nonemergency 8 5.1 7 IT.1 I5 3.0 
Myocardial infarcticpn 
Q wave 6 3.8 9 P.7 15 3.0 0.705 
Non-Q wave 6 3.8 6 8.8 12 2.5 0.305 _I 
B. Events After Discharge 
Death 3 1.9 4 I.2 7 1.4 0.8 
Bypass surgery 6 3.8 28 8.3 34 6.9 0.1 
Myocardial infarction 
Q wave 2 I.3 2 0.h 4 0.8 0.791 
Non-Q wave i Q.6 3 0.9 4 0.8 0.845 
.^ 
*Comparing the groups with acute and threatened vessel closure. 
because of severe to~~osity of he vess 
of intended stem placement) and inabil 
with the stem/balloon catheter. Inability to reach the lesion 
with the device accounted r nine patients not receiving 
stents and inabihty ocross e lesion prevented stenting in
another nine. The undeployed stems were all successfully 
withdrawn from 
~~~~~ca~ outco . Pn-hospital clinical suc- 
cess (that is, angiogra~hic success with no death, by 
graft surgery or myocardial i~fa~ct~o~) was a d in 420 
(87.3%) ofthe 481 patients with a~g~og~a~hic s. Table 
3A presents the incidence of dea 
myocardial infarction during the in- 
ately after stent placement and before hospital discharge. 
Results are presented for the acute closure and threatened 
vessel closure groups separately and combined. The in- 
ass surgery was s 
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DAY ON WHICH CABQ OCCURRED 
Figure 4, Kaplan-Meier curve for the incidence of coronary artery 
bypass urgery (CABG) in the &month period after stenting for 
acute or threatened vessel closure. Upper and lower curves represent 
the 95% confidence interval. 
catheterization; 4 patients (1%) undergoing early recatheter- 
ization had repeat angioplasty of the stented region and are 
waiting an additional 6 months for follow-up evaluation and 
1 additional patient has not yet had follow-up catheteriza- 
tion. 
For the entire group of patients undergoing 6-month 
angiographic follow-up study, rhe percent diameter s nosis 
averaged 46 2 31% (48 + 29% for the acute closure group 
[n = lG8] and 45 + 31% for the threatened closure group 
[n = 2281). The incidence of restenosis, defined as X0% 
diameter stenosis at follow-up study, was 38% for the acute 
closure group (41 of 108) and 39.5% for the threatened 
closure group (90 of 228). Overall, the incidence of resteno- 
sis WBS 39%. Repeat angioplasty was performed in 42 
Figure 5. Kaplan-Meier cu ve for the incidence of myocardial 
infarction (Ml) in the Gmonth period after stewing for acute or 
threatened vessel closure. Upper and lower curves represent the 95% 
confidence interval. 
0.04 . . I 
0 30 6.0 90 120 150 180 
ZAY ON W!ICH MI OCCURRED 
Table 4. Blood Lo% Complications Requiring Transfusion 
~ 
Blood Loss Site Patients (no.) 
Arterial access site* 51 
Gastrointestinal 9 
Depressed hemoglobin 7 
Retroperitoneum 4 
Hevaturia 2 
Hemorrhagic cystitis 2 
Intracranial 1 
Soft tissue I 
Total 83 
*Subsequently. three of these patients also had episodes of gastrointesti- 
nal bleeding and one had intracranial bleeding. 
patients (8.5%) withi 
procedure. 
The influence of stent dia 
restenosis in patients having &month fo 
was evaluated by nonparametric &i-square analysi 
nosis of the stented artery was reported in 35% 
patients) with 4-mm diameter stents, 25% (13 of 52 
with 3.5-mm stents, 45.7% (63 of 138 
stents, 38.1% (45 of 118 patients) wit 
37.5% (3 of 8 patients) with 2-mm stent 
of these results indicated that restenos 
stent diameter (,$ = 4.29, <,$o,osc~, = 9.49). 
The implantation f multiple stents during a single 
dure was not associated with an increased restenosi 
Twelve (40%) of 30 patients receiving two or more stents 
during a single proced 
artery corn~a~e~ with 
single stem. Chi-square analysis howed these rates to be 
not significantly different. 
~~~~~icat~o~s. The incidence of bypass urgery, myo- 
cardial infarction and death has lready been discussed with 
regard to clinical outcome. Other complications included 
blood loss requiring transfusion and subacute thrombosis at 
the stent site. 
Eighiy-ihee patients (l,S.g%:U; AG~U~I~~ LLUIIJIUJLVIIO u.cGI “--..:--A +..~,rF~,,;,nC Jt‘x8. 
the angioplastylstenting procedure. Table 4 presents a strat- 
ification of the reasons given for requiring transfusion. Blood 
loss from the arterial ccess ite accounted for 69% (5‘7 of 83) 
of the reported bleeding complications. Four retroperitoneal 
hematomas were reported. Primary gastrointestinal blood 
loss was reported innine patients and was the second most 
frequent reason for transfusion, followed by depressed he- 
moglobin in seven patients. The incidence of blood loss 
requiring transfusion decreased throughout the s udy, espe- 
cially once the value of gradual mobilization was identified. 
Before March 1990, the incidence of blood loss requiring 
transfusion was 24.6% (29 of 1118 bleeding complicationsj. At 
that time, the importance of graduated moCilizaGor, was 
reported at an investigators’ meeting and incorporated into 
the poststenting protocol. Since then, the bleeding compli- 
cation rate has decreased to 14.4% (54 of 376 bleeding 
complications) and continues to improve. 
thrombosis. Three (6. 
more stems during a single procedure exhibited thrombosis 
of the stented artery compared with (8.9%) of449 patients 
receiving a single stem. These rates were not s~g~i~cant~y 
different by cbi-square analysis. 
~~ti~e~ter series of 
acute or threatene 
closure represents he learning curve experience with the 
first clinically available pro’totype of ihe device. series 
includes ubjects treated uring a ti atient 
selection criteria and management strategies were being 
developed. It also includes a l rge ~ro~o~io~ f investiga- 
f acute vessel cl 
and an incidence 
% to 53.8%. The 
ct to currently avai 
a second-line therapy only in 
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though some of the blood loss was associated With a colnph% 
and prolonged angioplasty procedure and most (69%) of the 
bleeding complications i volved the femoral artery puncture 
site. Gastrointestinal bleeding requiring transfusion OCCUrred 
in 1.8% of patients, retroperiioneaI hemorrhage in 0.8% and 
an intracranial hemorrhage in 0.2% (one patient). Although 
hemorrhagic complications were a SigtIifiCatIt problem, there 
was a wide institutional variation i the incidence of hemor- 
rhagic events, ranging from 0% to 32% in centers performing 
the procedure in 220 patients, and a learning curve e&t 
evidelnced bya marked reduction i bleeding complications 
over time. Several factors probably played a role in this 
improvement, including better patient selection, the use of 
prolonged C-clamp compression on the femoral puncture 
site, moderating the level of anticoagulation and initiating 
72 h of bed rest after the procedure. Hemorrhagic prob- 
lems may be further r duced in the future through the use 
of better femoral puncture closure techniques and the use of 
less rhrombogenic stents that will facilitate less aggressive 
anticoagulant regimens. 
Thrombosis of the stented artery occurred in 8.7% of 
patients inthis series. This complication was responsible for 
myocardial infarction in 4% of patients and referral for 
bypass in 3%. In MO% of the patients with stent hrombosis, 
the vessel could be reopened with repeat angioplasty or
thrombolytic therapy. The incidence of stent thrombosis 
also decreased over time and varied greatly among centers, 
ranging from 0% to 15.2% in centers treating 22 
Thrombosis occurred an average of5.2 ‘-’ 6.2 days (range 0
to 29) after stenting, in some instances shortly after discon- 
tinuation of heparin. Appropriate p ient selection, stenting 
technique and vigilant management of he a~ti~i~te~et and 
anticoagulant regimen appear to be important in avoiding 
stent thrombosis. Ofparticular importance is the presence of
residual or uncovered dissection and the placement of stents 
in vessels with preexisting untreated thrombus or poor distal 
runoff. Forty percent of the stems with subacute hrombosis 
had angiographicaliy evident thrombus in the vessel before 
stenting. Prolonged (12 to 24 h) intracoronary side-hole 
delivery of urokinase may be used as an adjunct to stenting 
in such patients. 
The incidence ofthrombosis was statistically independent 
of the stent diameter. However, for the 2-mm stents, this 
result was borderline. That is, if one additional p tient with 
a 2-mm stem had exhibited thrombosis, the result would 
have been significant. Thus, the 25% incidence of thrombo- 
SiS in patients receiving &mm stents warrants caution when 
use of this size stent is contemplated. The implantation f 
multiple steds was not associated with an increase in 
thrombosis in the stented vessel. 
e&mask Despite favorable initial angiographic and 
clinical results. 39% of patients undergoing follow-up recath- 
etefization showed evidence of restenosis defined as >JO% 
diameter narrowing. However, in the critical situation of 
acute or threatened closure, th  primary value of the CO~O- 
nary Stent is its ability to provide arapidly applied nonsur- 
gical alternative to correct or prevent the ablest closure 5f a 
coronary artery after an ~~s~ccessfu~ a~ io~~ast~ proc 
not its ability to prevent restenosis. Late cardiac d 
myocardial infarction was ~~cornrno~. Thereste~os~s rate 
was not i~~~e~ced by the di 
lantation ofm~itip~e s 
enon after stenting for acute or threatened vessel closure 
with this device appears to follow a similar p 
seen after outine lective balloon a~gio~iasty. 
who required further revasculariz 
repeat balloon dilation. A~tboMg~ 
morphology that predispo 
cohorts of patients who c 
plasty alone have been repo 
>5 
ave reste~~s~s rates of 
s to ere are several limitations to 
this study. This tudy was not desisted as a ran 
trial. When the study began, the only viable alternative to
stenting for acute vessel closure was emergency bypass 
surgery. Because the nee 
ered an adverse outcome 
priate comparisons betwe 
and a group of patients undergoing emerge 
gery were not possible. Because prolonged 
was not considered a standard alternative treatment when 
this study began, such patients were not acce 
control group. The study may have been limited 
the increasing complexity of lesions 
oved angisplasty 
alternative therapies not 
available at the beginning of the study. Nevertheless, the 
measured end points were reasonably hard (namely, the 
incidence of myocardiatl infarction, coronary artery bypass 
graft surgery and death) and comparisons 
previous reports of similar patients wit 
occlusion associated with coronary angioplasty. 
Conclushms. This early multicenter xperience suggests 
that his rknt Is a flsefil! adjunct gercutaneous intervention 
to prevent or minimize complications a sociated with flow- 
limiting coronary artery dissections that cannot be corrected 
with conventional percutaneous techniques. Although this 
study was not randomized, it emonstrates a high technical 
success rate and encouraging results with respect to the low 
incidence ofemergency oronary artery bypass urgery and 
myocardial infarction. 
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